OliX Pharmaceuticals Hires Former GSK Executive Min Ji-young as CDO to Accelerate Global RNAi Development – finance.biggo.com

OliX Pharmaceuticals, a company specializing in RNA interference (RNAi)-based drug development, has brought on a development expert from a major global pharmaceutical firm as its Chief Development Officer (CDO), accelerating the global expansion of its key pipelines.
OliX announced on the 10th that it has appointed Dr. Min Ji-young, who has led drug development for approximately 20 years at GlaxoSmithKline (GSK), Institut Pasteur Korea, and the U.S. National Institutes of Health (NIH), as its new Senior Vice President and CDO. Dr. Min will be responsible for establishing and executing global development strategies for OliX’s major pipelines, playing a pivotal role in elevating the company’s technology transfer and partnering competitiveness.
Dr. Min is an expert with hands-on experience across the entire drug development process, from target discovery through preclinical and translational research, chemistry, manufacturing, and controls (CMC), global Phase 1-3 clinical trials, to regulatory strategy. At GSK, she oversaw global development and clinical R&D, leading development strategies for multiple drug programs, including RNAi and nucleic acid therapeutics. She led a global development team comprising preclinical, translational research, CMC, clinical, regulatory, and external partner functions, taking responsibility for key decision-making at each stage from candidate discovery through clinical entry, subsequent trials, and regulatory engagement.
Notably, Dr. Min possesses extensive experience not only in GalNAc-based liver-targeted delivery technology but also in extrahepatic tissue delivery using lipid conjugates, as well as central nervous system (CNS) and skin delivery platform development. OliX explained that this expertise aligns closely with the company’s R&D strategy, which is currently expanding the application scope of its RNAi platform to the liver, adipose tissue, skin, eye, and CNS.
Prior to joining GSK, Dr. Min built and led an R&D organization at Institut Pasteur Korea encompassing small molecule and nucleic acid therapeutic discovery, genome-wide siRNA screening, and support for preclinical and Investigational New Drug (IND) submissions. At the NIH’s National Institute of Allergy and Infectious Diseases (NIAID), she conducted preclinical research, IND submission support, and early clinical preparation, honing development strategies aligned with global regulatory standards.
OliX expects that Dr. Min’s addition will enable the company to proactively identify key data and potential risks required for subsequent clinical and regulatory processes from the early research stage, establishing development strategies that meet the licensing standards of global pharmaceutical companies.
Going forward at OliX, Dr. Min will be responsible for strategic decision-making across the drug development spectrum, including securing core preclinical data, IND submission strategy, CMC development and manufacturing system establishment, clinical trial design and operations, biomarker and dose selection, engagement with global regulatory agencies, and management of external partners and contract research organizations (CROs). She also plans to strengthen the alignment of development strategies between the company’s South Korean and U.S. organizations and enhance the collaboration framework across research, preclinical, CMC, clinical, and regulatory functions. The goal is to increase the early-stage development maturity of each pipeline and build data packages at a level that enables global partners to continue subsequent development, thereby further strengthening technology transfer competitiveness.
“OliX possesses both a proprietary RNAi platform capable of targeting diverse tissues and pipelines at the clinical or clinical-entry stage, giving it high potential in terms of global drug development,” said Dr. Min. “Based on my experience accumulated across the entire drug development process, I will contribute to establishing development strategies that consider subsequent clinical and regulatory requirements from the early stage, and to enhancing the probability of development success and global partnering competitiveness of the key pipelines.”
Lee Dong-ki, CEO of OliX, stated, “Dr. Min is a development expert with experience across preclinical, CMC, global clinical, and regulatory areas in the RNAi and nucleic acid therapeutics field. By incorporating the development standards and requirements of global pharmaceutical companies from the early research stage, she will enhance the development maturity of the OASIS platform and our major pipelines.”
OliX is currently advancing clinical entry and subsequent development of its key pipelines simultaneously. The MASH/obesity therapy ‘OLX702A’ is awaiting receipt of the Clinical Study Report (CSR) in the second half of this year following completion of a Phase 1 trial in Australia, while the hair loss therapy ‘OLX104C’ is concluding a Phase 1b trial in Australia. The macular degeneration therapy ‘OLX301A’ is preparing to enter a multinational, multicenter Phase 2a trial in patients with geographic atrophy (GA) in the second half of this year. The ALK7-targeted obesity therapy ‘OLX501A’ is progressing with preclinical and clinical entry preparations, targeting an IND submission for a Phase 1 trial in the first half of 2027.
Industry observers view this appointment as a significant boost to OliX’s global development capabilities. In particular, analysts note that having a development head from a major pharmaceutical company join from the early stage will contribute to enhancing the completeness and reliability of data required in future technology transfer negotiations.
Once added, BigGo Finance appears first in Google Search Top Stories, so you get the broadest, most up-to-the-minute, and most comprehensive global financial news first.
The news and data on this website are for reference only and do not constitute investment advice or an offer to buy or sell. Information is sourced from exchanges and public sources, and may be delayed, interrupted, or updated. While we strive for accuracy, we do not guarantee timeliness, correctness, or completeness. Content may include external links for which we are not responsible. By using this site, you agree that we and our partners are not liable for any losses. Investment carries full responsibility; please carefully assess risks and consult professionals. If there are errors in the content, please contact us for correction.

source
This is a newsfeed from leading technology publications. No additional editorial review has been performed before posting.